Results 181 to 190 of about 106,568 (297)

Synthetic lethality from the combination of a histone methyltransferase SUV39H2 inhibitor and a poly (ADP-ribose) polymerase inhibitor for uterine leiomyosarcoma. [PDF]

BMC Cancer
Toyohara Y, Sone K, Kumegawa K, Yamamoto Y, Hachijo R, Kukita A, Taguchi A, Ikemura M, Miyamoto Y, Tanikawa M, Iriyama T, Mori M, Hamamoto R, Ushiku T, Oda K, Hirota Y, Maruyama R, Osuga Y.   +17 more
europepmc   +1 more source

Different Immune Cells Modified With Chimeric Antigen Receptors Are Being Applied to Ovarian Cancer: Which Is the Most Effective?

Cancer Medicine, Volume 15, Issue 5, May 2026.
ABSTRACT Ovarian Cancer (OC), the deadliest gynecological malignancy, poses a major therapeutic challenge in advanced stages owing to its high recurrence rate and metastatic potential. In this regard, it is noteworthy that immunotherapy has recently gained significant attention in OC treatment, a phenomenon attributable to notable advances in over‐the ...
Liying Wang, Yisen Cao, Yuan Ren, Yuhang Zhang, Liang Wang   +4 more
wiley   +1 more source

Recurrent patterns and prognostic factors based on CA-125 and RECIST progression in ovarian cancer patients treated with poly (ADP-ribose) polymerase inhibitors. [PDF]

J Ovarian Res
Zhang B, Lv W, Fu Z, Zhou Y, Du J, Yao Q, Qian Q, Bu H.   +7 more
europepmc   +1 more source

Cryptocaryone Exhibits ROS/MAPK‐Dependent Antiproliferative and Apoptosis‐Inducing Effects on Triple‐Negative Breast Cancer Cells and Proof‐of‐Concept Breast Cancer Mouse Model

Drug Development Research, Volume 87, Issue 3, May 2026.
ABSTRACT Omics’ technologies have enabled clinicians to gain previously unprecedented insights into the molecular complexity and clinical heterogeneity of triple‐negative breast cancer (TNBC). Increasingly it is being realized that TNBC does not respond well to current targeted therapies.
Ya‐Ting Chuang, Wangta Liu, Tsu‐Ming Chien, Ammad Ahmad Farooqi, Hsun‐Shuo Chang, Jun‐Ping Shiau, Hsueh‐Wei Chang   +6 more
wiley   +1 more source

Identification and Characterization of Novel Inhibitors of Human Poly(ADP-Ribose) Polymerase-1. [PDF]

Molecules
Morgan I, Rennert R, Berger R, Hassanin A, Davari MD, Eisenschmidt-Bönn D, Wessjohann LA.   +6 more
europepmc   +1 more source

Potential Biological Targets of Anticancer Metal‐Based Drug Candidates: A Systematic Review

Drug Development Research, Volume 87, Issue 3, May 2026.
ABSTRACT The discovery of Cisplatin marked the beginning of the metallodrug era in oncology. Despite their clinical success, platinum‐based compounds present important limitations, including drug resistance and systemic toxicity. These challenges have stimulated interest in alternative metal complexes capable of interacting with biomolecular targets ...
Allysson L. dos S. Ferreira, Bruna B. Dantas, Jailton De Souza‐Ferrari, Edilson B. Alencar Filho   +3 more
wiley   +1 more source

A phase I clinical trial evaluating the effect of food on the pharmacokinetics of TSL-1502, a glucuronide prodrug of a novel oral poly (ADP-ribose) polymerase inhibitor, in healthy Chinese subjects. [PDF]

Front Pharmacol
Zhou J, Mi X, Liu H, Liu R, Zhang H, Ding Y.   +5 more
europepmc   +1 more source

Poly [ADP-Ribose] Polymerase 1 [PDF]

, 2020
openaire   +1 more source

Dietary Ergothioneine as a Novel Anti‐Aging Nutraceutical: Mechanisms, Bioavailability, and Future Perspectives

Food Frontiers, Volume 7, Issue 3, May 2026.
ABSTRACT Ergothioneine (EGT), a natural thiol derivative, has gained attention as a geroprotective nutraceutical. Preclinical research shows EGT scavenges free radicals, maintains mitochondrial integrity, slows telomere erosion, and regulates proteostasis via autophagy and senescent cell clearance.
Tian‐Tian Tian, Liang Chen, Zhen‐Zhen Dong, Chao Yang   +3 more
wiley   +1 more source

Poly(ADP-ribose) polymerase (PARP) inhibitors and ovarian cancer

Taiwanese Journal of Obstetrics & Gynecology, 2017
Chia-Hao Liu, Yi Chang
doaj   +1 more source